You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

CLINICAL TRIALS PROFILE FOR HQP1351


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for HQP1351

Trial ID Title Status Sponsor Phase Summary
NCT03594422 ↗ A Study of HQP1351 in Patients With GIST or Other Solid Tumors Recruiting HealthQuest Pharma Inc. Phase 1 This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
NCT03594422 ↗ A Study of HQP1351 in Patients With GIST or Other Solid Tumors Recruiting Ascentage Pharma Group Inc. Phase 1 This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
NCT03882281 ↗ Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia Completed HealthQuest Pharma Inc. Phase 1 The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately(Selection of high-fat meal spectrum:《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
NCT03882281 ↗ Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia Completed Ascentage Pharma Group Inc. Phase 1 The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately(Selection of high-fat meal spectrum:《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for HQP1351

Condition Name

Condition Name
Intervention Trials
Chronic Myeloid Leukemia, Chronic Phase 4
Leukemia, Myeloid, Chronic 1
Myeloid Leukemia 1
Olverembatinib 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Leukemia, Myeloid 7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7
Leukemia 6
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for HQP1351

Trials by Country

Trials by Country
Location Trials
China 39
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
Washington 1
Texas 1
Ohio 1
Georgia 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for HQP1351

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Recruiting 3
Active, not recruiting 3
Completed 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HQP1351

Sponsor Name

Sponsor Name
Sponsor Trials
Ascentage Pharma Group Inc. 7
HealthQuest Pharma Inc. 4
Shenzhen Second People's Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 11
Other 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.